Stock Events

Stock Events

Gilead Sciences 

€65.22
2779
+€0+0% Friday 17:29

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
32.58
Dividend Yield
-
Dividend
-

Upcoming

13
JUN
Dividend Ex
Estimated
 
27
JUN
Dividend Payment
Estimated
 

Dividends

0%Dividend Yield
Mar 26
€0.71
Dec 25
€0.71
Sep 25
€0.71
Jun 25
€0.71
Mar 25
€0.71
10Y Growth
N/A
5Y Growth
4.82%
3Y Growth
5.66%
1Y Growth
2.38%

Earnings

7MayExpected
Q2 2024
Q4 2024
Q4 2024
Q2 2025
Q2 2025
Q4 2025
Next
1.74
1.83
1.92
2.01
Expected EPS
1.909476
Actual EPS
N/A

Financials

20.97%Profit Margin
Profitable
2018
2019
2020
2021
2022
2023
24.98BRevenue
5.24BNet Income

Analyst Ratings

121.22Average Price Target
The highest estimate is 136.58.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GILD.MI. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie competes directly with Gilead in the areas of hepatitis C treatments and is also a major player in immunology and oncology.
Merck
MRK
Mkt Cap276.38B
Merck & Co. offers competitive products in the antiviral space, including treatments for HIV and hepatitis C, directly challenging Gilead's core market.
Pfizer
PFE
Mkt Cap153.59B
Pfizer competes across several therapeutic areas including oncology, immunology, and antiviral drugs, overlapping with Gilead's product portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol Myers Squibb is a key competitor in the oncology and immunology sectors, areas where Gilead Sciences is actively expanding its presence.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the HIV and hepatitis C markets, among others, where Gilead has significant interests.
AMGEN
AMGN
Mkt Cap185.74B
Amgen competes with Gilead in the biopharmaceutical space, particularly in the areas of oncology and inflammatory diseases.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline, through its ViiV Healthcare joint venture, is a strong competitor in the HIV treatment market, directly challenging Gilead's leadership.
Novartis
NVS
Mkt Cap280.79B
Novartis competes with Gilead in several areas including oncology and gene therapy, with both companies investing heavily in research and development.
Roche
RHHBY
Mkt Cap332.61B
Roche, through its Genentech unit, competes in the oncology and antiviral markets, areas where Gilead has key products.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca competes with Gilead in the oncology sector, with both companies developing treatments for various cancers.

About

There is no Profile data available for GIS.SG.
Show more...
CEO
Mr. Daniel P. O'Day
Employees
14400
Country
United States
ISIN
US3755581036
WKN
000885823

Listings

F
DE
GIS.F
TO
CA
GILD.TO
F
DE
GIS0.F
LSE
GB
0QYQ.LSE

0 Comments

Share your thoughts

FAQ

What is Gilead Sciences stock price today?▼
The current price of GILD.MI is €65.22 EUR — it has increased by +0% in the past 24 hours. Watch Gilead Sciences stock price performance more closely on the chart.
What is Gilead Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gilead Sciences stocks are traded under the ticker GILD.MI.
What is Gilead Sciences revenue for the last year?▼
Gilead Sciences revenue for the last year amounts to 24.98B EUR.
What is Gilead Sciences net income for the last year?▼
GILD.MI net income for the last year is 5.24B EUR.
Does Gilead Sciences pay dividends?▼
Yes, GILD.MI dividends are paid quarterly. The last dividend per share was 0.71 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Gilead Sciences have?▼
As of April 28, 2026, the company has 14,400 employees.
In which sector is Gilead Sciences located?▼
Gilead Sciences operates in the Health & Wellness sector.
When did Gilead Sciences complete a stock split?▼
Gilead Sciences has not had any recent stock splits.
Where is Gilead Sciences headquartered?▼
Gilead Sciences is headquartered in Foster City, United States.